Evaluation of YKL-40 Serum Level in Patients with Type 1 Diabetes and Its Correlation with Their Metabolic and Renal Conditions

Arani, Kobra Shiasi; Talebian, Farbod; Khamechi, Seyed Peyman; Nikoueinejad, Hassan; Sehat, Mojtaba; Azarbad, Zohreh; Einollahi, Behzad

doi:10.5812/numonthly.12431

Cited by 5 publications

(6 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…And our study, with more strong power, con rm that patients with DM have signi cantly higher levels of YKL-40 compared with healthy controls. Some studies also show that YKL-40 levels are positively associated with diabetes duration [26,29] and glycated hemoglobin (HbA1c) [30][31][32]34,37]. It seems that YKL-40 might be a good metabolic indicator of DM.…”

Section: Sensitivity Analysismentioning

confidence: 99%

See 1 more Smart Citation

Increased levels of YKL-40 in patients with diabetes mellitus: a systematic review and meta-analysis

Luo

Zhang

Sheng

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: Diabetes mellitus (DM) could be classified as type 1 diabetes mellitus (T1DM), type 2 diabetes mellitus (T2DM), gestational diabetes mellitus (GDM) and others according to etiology and pathology. Diabetic nephropathy (DN) is one of the most serious complications of DM. YKL-40 is a marker of inflammation and some studies have indicated that DM was related with inflammation. The objective of our study is to perform a systematic review and meta-analysis to confirm the relationship between YKL-40 and DM as well as DN.Methods: Pubmed, Embase, CNKI and Chinese wanfang databases were searched for eligible studies by two independent authors. Studies were included in this meta-analysis if they fulfilled the following inclusion criteria: (1) a study involving the role of YKL-40 in DM (or DN) designed as a case-control study or cohort study; (2) the data of serum YKL-40 levels were available; (3) studies were published in English or Chinese.Results: Twenty-five studies involving 2498 DM patients and 1424 healthy controls were included. Compared with healthy controls, DM patients had significantly higher levels of YKL-40 (DM: SMD=1.62, 95%CI, 1.08 to 2.25, P=0.000; GDM: SMD=2.85, 95%CI, 1.01 to 4.70, P=0.002). Additionally, DM patients with different degree of albuminuria had significantly higher levels of YKL-40 compared with healthy controls (normoalbuminuria: SMD=1.58, 95%CI, 0.59 to 2.56, P=0.002; microalbuminuria: SMD=2.57, 95%CI, 0.92 to 4.22, P=0.002; macroalbuminuria: SMD=2.69, 95%CI, 1.40 to 3.98, P=0.000) and serum YKL-40 levels increased with increasing severity of albuminuria among DM patients (microalbuminuria vs normoalbuminuria: SMD=1.49, 95%CI, 0.28 to 2.71, P=0.016; macroalbuminuria vs microalbuminuria: SMD=0.93, 95%CI, 0.34 to 1.52, P=0.002).Conclusions: DM patients have higher levels of YKL-40 compared with healthy controls. Additionally, levels of YKL-40 are significantly higher in DM patients with different degree of albuminuria than in the healthy controls and the levels of YKL-40 are positively related with the severe degree of albuminuria. Therefore, our current meta-analysis suggests that their sera should be detected for YKL-40, if DM, especially DN, is suspected in patients.

show abstract

Section: Sensitivity Analysismentioning

confidence: 99%

“…It seems that YKL-40 might be a good metabolic indicator of DM. However, some nd that there is no signi cant association between YKL-40 levels and HbA1c [26,28,29]. Therefore, studies with more DM patients need to be performed in the future.…”

Section: Sensitivity Analysismentioning

confidence: 99%

Increased levels of YKL-40 in patients with diabetes mellitus: a systematic review and meta-analysis

Luo

Zhang

Sheng

et al. 2020

Preprint

View full text Add to dashboard Cite

show abstract

“…In addition, studies by Lorbeer et al [23] and Pérez De Ciriza et al [24] demonstrated higher circulating concentrations of TIE2 and FGF-23 in T2DM groups and T1DM groups, respectively. CHI3L1 has also been investigated in the setting of T1DM [25] and T2DM [26], showing increased concentrations in both disease groups. Though little literature was found on AGRP and FS being investigated in CVD population, the study conducted by Fujikawa et al [27] showed that increased ARGP mRNA transcription can cause higher AGRP level in T1DM mice to induce obesity.…”

mentioning

confidence: 99%

Investigating potential protein markers of cardiovascular disease in children with type 1 diabetes mellitus

Letunica

Cai

Cameron

et al. 2021

Proteomics Clinical Apps

View full text Add to dashboard Cite

Background: Type 1 diabetes mellitus (T1DM) is a metabolic disease characterized by dysglycaemia. Cardiovascular disease (CVD) is a major complication among T1DM patients and the leading cause of mortality later in life. Methods:The study subjects consisted of T1DM children with poor glycemic control (HbA1c > 7.5%) and healthy age and gender matched controls. Venous blood samples were collected and tested by utilizing a novel immunoassay panel with 96 protein biomarkers. Data were analyzed using non-linear regression analysis and the expression of biomarkers was compared between T1DM and healthy control groups using an unpaired student's t-test. Dynamic principal component analysis (PCA) was operated based on the differentially expressed proteins. Results: Ten T1DM children and 10 healthy controls were analyzed. Twelve CVD markers show significant differential expression between T1DM patients and healthy controls (p < 0.05). Dynamic PCA clustering based on differentially expressed proteins demonstrated an obvious clustering between the two populations. Conclusions: This preliminary study reveals the feasibility of utilizing a novel immunoassay panel to investigate potential biomarkers for predicting incipient CVD in children with T1DM. In future, longitudinal studies are required to track the relationships between measurements of the selected protein markers and the development of CVD in T1DM patients. K E Y W O R D S biomarkers, cardiovascular disease, paediatrics, type 1 diabetes mellitus Type 1 diabetes mellitus (T1DM) results in absolute insulin deficiency, polyuria, polydipsia, and weight loss [1]. Globally, the prevalence of T1DM is increasing [2], and is associated with a substantially heightened risk of microvascular and macrovascular complications such as neuropathy, nephropathy, retinopathy, cerebrovascular disease, and cardiovascular disease (CVD) [3]. Among T1DM patients, CVD is one of the major long-term complications and the main causes of mortality later in life [4]. Despite this, established biomarkers are limited in predicting T1DM related CVD. Glycated hemoglobin (HbA1c) was frequently used as a biomarker for risk assessment because levels can indicate average 3-month blood sugar levels [5-7]. However, the efficacy of intensive glycemic control still lacks consensus and the target HbA1c levels for T1DM patients varies significantly between organizations [5,8]. Other biomarkers such as lipid level, albumin, body mass index, inflammatory markers, blood pressure, or osteoprotegerin are affected by covariables such as obesity, retinopathy, or nephropathy, making them difficult to utilize as independent CVD predictors [7,9,10]. Early detection of disease progression is of importance in the prevention of the CVD complication in T1DM patients. In this

show abstract

“…The great majority of studies (22 studies) included in our meta-analysis provided data of HhA1c values. In some studies, HbA1c values were higher than upper limits of normal range, but 5 studies [23-25, 27, 30] showed that YKL-40 levels are positively correlated with HbA1c, while 3 studies [19,21,22] did not show any correlation. Therefore, although YKL-40 is also an inflammatory cytokine, the relationship between hyperglycemia and YKL-40 needs to be confirmed.…”

Section: Discussionmentioning

confidence: 99%

Increased levels of YKL-40 in patients with diabetes mellitus: a systematic review and meta-analysis

Luo

Zhang

Sheng

et al. 2021

Diabetol Metab Syndr

View full text Add to dashboard Cite

Background Diabetes mellitus (DM) could be classified as type 1 diabetes mellitus (T1DM), type 2 diabetes mellitus (T2DM), gestational diabetes mellitus (GDM) and others according to etiology and pathology. Diabetic nephropathy (DN) is one of the most serious complications of DM. YKL-40 is a marker of inflammation and some studies have indicated that DM was related with inflammation. The objective of our study is to perform a systematic review and meta-analysis to confirm the relationship between YKL-40 and DM as well as DN. Methods Pubmed, Embase, CNKI and Chinese wanfang databases were searched for eligible studies by two independent authors. Studies were included in this meta-analysis if they fulfilled the following inclusion criteria: (1) a study involving the role of YKL-40 in DM (or DN) designed as a case–control study or cohort study; (2) the data of serum YKL-40 levels were available; (3) studies were published in English or Chinese. Finally, twenty-five studies were included in this meta-analysis. Results Compared with healthy controls, DM patients had significantly higher levels of YKL-40 (DM: SMD = 1.62, 95% CI 1.08 to 2.25, P = 0.000; GDM: SMD = 2.85, 95% CI 1.01 to 4.70, P = 0.002). Additionally, DM patients with different degree of albuminuria had significantly higher levels of YKL-40 compared with healthy controls (normoalbuminuria: SMD = 1.58, 95% CI 0.59 to 2.56, P = 0.002; microalbuminuria: SMD = 2.57, 95% CI 0.92 to 4.22, P = 0.002; macroalbuminuria: SMD = 2.69, 95% CI 1.40 to 3.98, P = 0.000) and serum YKL-40 levels increased with increasing severity of albuminuria among DM patients (microalbuminuria vs normoalbuminuria: SMD = 1.49, 95% CI 0.28 to 2.71, P = 0.016; macroalbuminuria vs microalbuminuria: SMD = 0.93, 95% CI 0.34 to 1.52, P = 0.002). Conclusions Our current meta-analysis demonstrates that serum level of YKL-40 is increased in DM and positively associated with the severe degree of albuminuria. Therefore, we suggest that YKL-40 could be considered to be detected, along with other inflammatory markers, if DM, especially DN, is suspected.

show abstract

Evaluation of YKL-40 Serum Level in Patients with Type 1 Diabetes and Its Correlation with Their Metabolic and Renal Conditions

Cited by 5 publications

References 33 publications

Increased levels of YKL-40 in patients with diabetes mellitus: a systematic review and meta-analysis

Increased levels of YKL-40 in patients with diabetes mellitus: a systematic review and meta-analysis

Investigating potential protein markers of cardiovascular disease in children with type 1 diabetes mellitus

Increased levels of YKL-40 in patients with diabetes mellitus: a systematic review and meta-analysis

Contact Info

Product

Resources

About